ISSN 1671-5411 CN 11-5329/R

Dear Colleagues,

Journal of Geriatric Cardiology (J Geriatr Cardiol, JGC) will launch a new website and adopt ScholarOne ManuscriptsTM system to manage the submission and peer review process from November 1, 2020. To review and check the status of your manuscripts submitted before November 2020, please visit...

more

Volume 17 Issue 11
Dec.  2020
Turn off MathJax
Article Contents
Andrea Herbst, Francesco Orso, Marta Migliorini, Simona Virciglio, Silvia Tognelli, Viola Camartini, Alessandra Pratesi, Francesco Fattirolli, Niccolò Marchionni, Andrea Ungar, Samuele Baldasseroni. ARNI and SGLT2i: a promising association to be used with caution. J Geriatr Cardiol 2020; 17(11): 728-732. doi: 10.11909/j.issn.1671-5411.2020.11.005
Citation: Andrea Herbst, Francesco Orso, Marta Migliorini, Simona Virciglio, Silvia Tognelli, Viola Camartini, Alessandra Pratesi, Francesco Fattirolli, Niccolò Marchionni, Andrea Ungar, Samuele Baldasseroni. ARNI and SGLT2i: a promising association to be used with caution. J Geriatr Cardiol 2020; 17(11): 728-732. doi: 10.11909/j.issn.1671-5411.2020.11.005

ARNI and SGLT2i: a promising association to be used with caution

doi: 10.11909/j.issn.1671-5411.2020.11.005
More Information
  • loading
  • [1]
    Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975. doi: 10.1002/ejhf.592
    [2]
    Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 1810-1852. doi: 10.1161/CIR.0b013e31829e8807
    [3]
    McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Commit-tees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective com-parison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; 15: 1062-1073. doi: 10.1093/eurjhf/hft052
    [4]
    Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128. doi: 10.1056/NEJMoa1504720
    [5]
    Neal B, Perkovic V, Matthews DR, et al. CANVAS-R. Trial Collaborative Group. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 2017; 19: 387-393. doi: 10.1111/dom.12829
    [6]
    Wiviott SD, Raz I, Bonaca MP, et al. DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357.
    [7]
    McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995-2008. doi: 10.1056/NEJMoa1911303
    [8]
    Milton Packer M, Anker SD, Butler J, et al. for the EMPEROR-Reduced trial investigators. Cardiovascular and renal outcomes with Empagliflozin in heart failure. N Engl J Med 2020; 396: 819-829.
    [9]
    Solomon SD, Jhund PS, Claggett BL, et al. effect of Dapagliflozin in patients with HFREF treated with sacubitril/valsartan: The DAPA-HF Trial. JACC Heart Fail 2020; 8: 811-818. doi: 10.1016/j.jchf.2020.04.008
    [10]
    Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J 2015; 36: 2576-2584. doi: 10.1093/eurheartj/ehv330
    [11]
    Martinez AP, Serenelli M, Nicolau JC, et al. Efficacy and safety of Dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 2020; 141: 100-111. doi: 10.1161/CIRCULATIONAHA.119.044133
    [12]
    Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 2018; 6: 489-498. doi: 10.1016/j.jchf.2018.02.004
    [13]
    Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295-2306. doi: 10.1056/NEJMoa1811744
    [14]
    Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436-1446. doi: 10.1056/NEJMoa2024816
    [15]
    McGill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors. Am J Cardiol 2019; 124 (Suppl 1): S45-S52.
    [16]
    Vardeny O, Vaduganathan M. Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. J Am Coll Cardiol HF 2019; 7: 169-172
    [17]
    Perlman A, Heyman SN, Stokar J. Clinical spectrum and mechanism of acute kidney injiury in patients with diabetes mellitus on SGLT-2 inhibitors. Isr Med Assoc J 2018; 20: 513-516.
    [18]
    Mullens W, Damman K, Testani J, et al. Evaluation of kidney function throughout the heart failure trajectory-a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 22: 584-603. doi: 10.1002/ejhf.1697
    [19]
    Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of Dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J 2020; 41: 2379-2392. doi: 10.1093/eurheartj/ehaa183
    [20]
    Jackson AM, Dewan P, Anand IS, et al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation 2020; 142: 1040-1054. doi: 10.1161/CIRCULATIONAHA.120.047077
    [21]
    Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574-1585. doi: 10.1002/ejhf.813
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Article Metrics

    Article views (145) PDF downloads(14) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return